Bank of New York Mellon’s Tonix Pharmaceuticals TNXP Stock Holding History

Bank of New York Mellon’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$533K	Buy	41,754 +11,328	+37%	+$146K	﹤0.01%	3723
2026 Q1	$418K	Buy	30,426 +6,362	+26%	+$97.9K	﹤0.01%	3687
2025 Q4	$376K	Buy	24,064 +3,921	+19%	+$72.3K	﹤0.01%	3749
2025 Q3	$487K	Buy	20,143 +2,395	+13%	+$88.9K	﹤0.01%	3609
2025 Q2	$639K	Buy	+17,748	New	+$465K	﹤0.01%	3373
2022 Q2	–	Sell	-2	Closed	-$305K	–	4698
2022 Q1	$305K	Hold	2	–	–	﹤0.01%	4003
2021 Q4	$399K	Hold	2	–	–	﹤0.01%	3938
2021 Q3	$603K	Hold	2	–	–	﹤0.01%	3700
2021 Q2	$1.07M	Buy	+2	New	+$1.47M	﹤0.01%	3369
2021 Q1	–	Hold	0	–	–	–	4041
2019 Q2	–	Hold	0	–	-$40K	–	4278
2019 Q1	–	Hold	0	–	–	–	4111
2018 Q4	–	Hold	0	–	–	–	4094
2017 Q1	–	Hold	0	–	-$8K	–	4328
2016 Q4	–	Hold	0	–	–	–	4249
2016 Q3	–	Hold	0	–	–	–	4242
2016 Q2	–	Hold	0	–	–	–	4208
2016 Q1	–	Hold	0	–	–	–	4029
2015 Q4	–	Hold	0	–	–	–	3926
2015 Q3	–	Hold	0	–	–	–	4086

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

LCM

Legato Capital Management San Francisco, California $1.21B AUM 82.36% 1-Year Est. Return

GLA

Great Lakes Advisors Chicago, Illinois $13.1B AUM 34.09% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

SIC

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon's TNXP Position: Q2 2026 in Review

Bank of New York Mellon increased its Tonix Pharmaceuticals (TNXP) stake by 37% in Q2 2026, buying an estimated $146K and bringing the position to 41,754 shares worth $533K. The position accounts for ﹤0.01% of the portfolio, ranked #3723.

Bank of New York Mellon first reported a position in TNXP in Q2 2021 and has held it in 9 quarters since. The position peaked at $1.07M in Q2 2021. 36 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

Bank of New York Mellon held 41,754 shares of Tonix Pharmaceuticals worth $533K as of Q2 2026.
Bank of New York Mellon bought 11,328 Tonix Pharmaceuticals shares in Q2 2026, an estimated $146K.
Tonix Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3723 holding.
Bank of New York Mellon first reported a position in Tonix Pharmaceuticals in Q2 2021 and has held it in 9 quarters since.
Bank of New York Mellon's Tonix Pharmaceuticals position peaked at $1.07M in Q2 2021.
36 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.